Pharmaceutical care model for patients with type 2 diabetes: Integration of the community pharmacist into the diabetes team - A pilot study

Pharmacy World and Science

Volumn 26, Issue 1, 2004, Pages 18-25

  Wermeille, Joel ^a   Bennie, Marion ^b,c   Brown, Ian ^b,d,e   McKnight, John ^b,d,e  

^a Hôpital du Jura Bernois SA   (Switzerland)

^b Lothian Pharmacy Practice Unit   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d NHS LOTHIAN   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anti hypertensive; Clinical pharmacy service; Community pharmacy service; Diabetes mellitus type 2; Hypoglycemic agents; Multi disciplinary; Patient education; Pharmaceutical care; Scotland

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ARTICLE; COMMUNITY CARE; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HUMAN; HYPERTENSION; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN ATTITUDE; SIDE EFFECT;

COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ORGANIZATIONAL; PATIENT CARE; PATIENT CARE TEAM; PHARMACISTS; PILOT PROJECTS; PROFESSIONAL ROLE; TREATMENT OUTCOME;

EID: 1342280622     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAR.0000013465.24857.a8     Document Type: Article

References (27)

1. Diabetes care and research in Europe: The Saint Vincent declaration. Diabet Med 1990; 7: 360.
2. Diabetes UK. Counting the cost: the real impact of non-insulin dependent diabetes, Kings Fund Policy Institute report commissioned by Diabetes UK, London, 1996.
3. Bennett N, Dodd T, Flately J, Freeth S, Bolling K. Health survey for England 1993. Social Survey Division of the Office of Population Censuses and Surveys, London: HMSO 1995.
4. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes: UKPDS 33. Lancet 1998; 352: 837-53.
6. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes: UKPDS 34. Lancet 1998; 352: 854-65.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
9. Keen H, Hall M. Saint Vincent: A new responsibility for general practitioners? Br J Gen Pract 1996: 447-8.
10. Diabetes Task Force. Guidelines for Community Pharmacists on the care of patients with Diabetes. London: Royal Pharmaceutical Society of Great Britain, 2001.
11. NHS Scotland. Our National Health: A Plan for Action, a Plan for Change. Edinburgh: Scottish Executive, 2000.
12. Scottish Office Department of Clinical Resource and Audit Group. Clinical Pharmacy Practice in Primary Care. Edinburgh: Scottish Office Department of Health, 1999.
13. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-92.
14. Cipolle RJ, Strand LM, Morley PC. Identifying, resolving, and preventing drug therapy problems: the pharmacist's responsibility. In: Pharmaceutical Care Practice. 1st ed. New York: McGraw-Hill, 1998.
15. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Morris LS, Schulz R. Patient compliance - an overview. J Clin Pharm Ther 1992; 17: 283-95.
17. Sarkadi A, Rosenqvist U. Field test of a group education program for type 2 diabetes: Measures and predicators of success on individual and group levels. Patient Educ Couns 2001; 44: 129-39.
18. Royal Pharmaceutical Society of Great Britain. From compliance to concordance - achieving partnership in medicine-taking. London: RPSGB, 1997.
19. Department of Health. National Framework for older people: Medicines and older people - implementing medicines-related aspects of the NSF for older people. London: Dept of Health, 2001.
20. Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J et al. A pharmaceutical profile of diabetic patients. J Chron Dis 1983; 36: 193-202.
21. Douglas E, Bennie M, McAnaw J, Hudson S. Diabetes mellitus. Pharm J 1998; 261: 810-8.
22. Colley C, Lucas L. Polypharmacy: the cure becomes the disease. J Gen Intern Med 1993; 8: 278-83.
23. Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20: 1512-7.
24. Van Veldhuizen-Scott MK, Widmer LB, Stacey SA, Popovich NG. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diabetes Educ 1995; 21: 117-23.
25. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996; 30: 238-43.
26. Monaghan MJ, Monaghan MS. Are pharmacists and pharmaceutical care having an impact on diabetes? Pharm Pract Manage Q 1998; 17: 8-16.
27. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Ass 1999; 39: 791-7.